New Risk • Jun 10
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: AU$14.1m (US$9.89m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 39% per year over the past 5 years. Market cap is less than US$10m (AU$14.1m market cap, or US$9.89m). Reported Earnings • Feb 20
First half 2026 earnings released: AU$0.003 loss per share (vs AU$0.008 loss in 1H 2025) First half 2026 results: AU$0.003 loss per share (improved from AU$0.008 loss in 1H 2025). Revenue: AU$9.72m (down 7.3% from 1H 2025). Net loss: AU$1.32m (loss narrowed 60% from 1H 2025). Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings. Board Change • Nov 01
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. Independent Non-Executive Director Geoff Sam was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Announcement • Oct 17
IDT Australia Limited, Annual General Meeting, Nov 19, 2025 IDT Australia Limited, Annual General Meeting, Nov 19, 2025. Location: baker mckenzie, level 19, 181 william street, melbourne vic 3000 Australia Reported Earnings • Aug 22
Full year 2025 earnings released: AU$0.019 loss per share (vs AU$0.016 loss in FY 2024) Full year 2025 results: AU$0.019 loss per share (further deteriorated from AU$0.016 loss in FY 2024). Revenue: AU$19.9m (up 42% from FY 2024). Net loss: AU$8.06m (loss widened 49% from FY 2024). Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has fallen by 18% per year, which means it is significantly lagging earnings. Reported Earnings • Feb 20
First half 2025 earnings released: AU$0.008 loss per share (vs AU$0.011 loss in 1H 2024) First half 2025 results: AU$0.008 loss per share (improved from AU$0.011 loss in 1H 2024). Revenue: AU$10.5m (up 83% from 1H 2024). Net loss: AU$3.25m (loss narrowed 16% from 1H 2024). Over the last 3 years on average, earnings per share has fallen by 25% per year but the company’s share price has only fallen by 18% per year, which means it has not declined as severely as earnings. New Risk • Feb 20
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -AU$12m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$12m free cash flow). Earnings have declined by 34% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (22% increase in shares outstanding). Market cap is less than US$100m (AU$45.1m market cap, or US$28.7m). Announcement • Nov 14
Myndbio Pty Ltd cancelled the acquisition of IDT Australia Limited (ASX:IDT). Myndbio Pty Ltd signed a letter of intent to acquire IDT Australia Limited (ASX:IDT) for AUD 52.7 million on June 4, 2024. A cash consideration valued at AUD 0.15 per share will be paid by Myndbio Pty Ltd. The transaction is subject to negotiation and execution of an implementation agreement, approval of merger agreement by target board, approval of offer by acquirer board and consummation of due diligence investigation.
Myndbio Pty Ltd cancelled the acquisition of IDT Australia Limited (ASX:IDT) on November 13, 2024. Announcement • Oct 18
IDT Australia Limited, Annual General Meeting, Nov 19, 2024 IDT Australia Limited, Annual General Meeting, Nov 19, 2024. Location: hybrid meeting, baker mckenzie, level 19, 181 william street, melbourne vic 3000. Australia Reported Earnings • Aug 27
Full year 2024 earnings released: AU$0.015 loss per share (vs AU$0.035 loss in FY 2023) Full year 2024 results: AU$0.015 loss per share (improved from AU$0.035 loss in FY 2023). Revenue: AU$14.1m (up 101% from FY 2023). Net loss: AU$5.41m (loss narrowed 36% from FY 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 24 percentage points per year, which is a significant difference in performance. New Risk • Jul 15
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 18% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 17% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (18% increase in shares outstanding). Market cap is less than US$100m (AU$55.8m market cap, or US$37.9m). Announcement • Jul 12
IDT Australia Limited has completed a Follow-on Equity Offering in the amount of AUD 7.029743 million. IDT Australia Limited has completed a Follow-on Equity Offering in the amount of AUD 7.029743 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 78,108,255
Price\Range: AUD 0.09
Discount Per Security: AUD 0.0054
Transaction Features: Rights Offering Reported Earnings • Feb 22
First half 2024 earnings released: AU$0.011 loss per share (vs AU$0.024 loss in 1H 2023) First half 2024 results: AU$0.011 loss per share (improved from AU$0.024 loss in 1H 2023). Revenue: AU$5.73m (up 136% from 1H 2023). Net loss: AU$3.86m (loss narrowed 34% from 1H 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 75 percentage points per year, which is a significant difference in performance. Reported Earnings • Aug 30
Full year 2023 earnings released: AU$0.035 loss per share (vs AU$0.005 loss in FY 2022) Full year 2023 results: AU$0.035 loss per share (further deteriorated from AU$0.005 loss in FY 2022). Revenue: AU$7.03m (down 42% from FY 2022). Net loss: AU$8.50m (loss widened AU$7.34m from FY 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 64 percentage points per year, which is a significant difference in performance. Announcement • Aug 29
IDT Australia Limited, Annual General Meeting, Nov 23, 2023 IDT Australia Limited, Annual General Meeting, Nov 23, 2023. New Risk • Aug 25
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Shareholders have been substantially diluted in the past year (71% increase in shares outstanding). Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Revenue is less than US$5m (AU$6.0m revenue, or US$3.8m). Market cap is less than US$100m (AU$26.8m market cap, or US$17.2m). Announcement • Jun 30
IDT Australia Limited, Annual General Meeting, Aug 01, 2023 IDT Australia Limited, Annual General Meeting, Aug 01, 2023, at 10:01 E. Australia Standard Time. Location: offices of Baker McKenzie, Level 19, 181 William Street Melbourne Australia Agenda: To consider Approval of Previous Share Issue - Tranche 1 Placement Listing Rule 7.1; to consider Approval of Previous Share Issue - Tranche 1 Placement Listing Rule 7.1A; to consider Approval of Share Issue Tranche 2 Placement; to consider Approval of Issue of Lead Manager Options; to consider Approval of Issue of Director Options to Mark Simari; to consider Approval of Issue of Director Options to Geoffrey Sam; and to consider Approval of Issue of Director Options to Jane Ryan. New Risk • Jun 16
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 52% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Shareholders have been substantially diluted in the past year (52% increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (16% average weekly change). Revenue is less than US$5m (AU$6.0m revenue, or US$4.1m). Market cap is less than US$100m (AU$23.4m market cap, or US$16.1m). New Risk • Jun 10
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 26% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (16% average weekly change). Minor Risks Shareholders have been diluted in the past year (26% increase in shares outstanding). Revenue is less than US$5m (AU$6.0m revenue, or US$4.0m). Market cap is less than US$100m (AU$19.8m market cap, or US$13.3m). Reported Earnings • Feb 24
First half 2023 earnings released: AU$0.024 loss per share (vs AU$0.005 profit in 1H 2022) First half 2023 results: AU$0.024 loss per share (down from AU$0.005 profit in 1H 2022). Revenue: AU$2.44m (down 72% from 1H 2022). Net loss: AU$5.81m (down AU$7.03m from profit in 1H 2022). Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has fallen by 18% per year, which means it is performing significantly worse than earnings. Board Change • Feb 10
High number of new and inexperienced directors There are 3 new directors who have joined the board in the last 3 years. The company's board is composed of: 3 new directors. No experienced directors. No highly experienced directors. Independent Non-Executive Director Jane Ryan is the most experienced director on the board, commencing their role in 2022. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model. Board Change • Nov 16
High number of new and inexperienced directors There are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. 1 experienced director. No highly experienced directors. Independent Chairman of the Board Alan Fisher is the most experienced director on the board, commencing their role in 2015. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model. Board Change • Nov 01
High number of new and inexperienced directors There are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. 1 experienced director. No highly experienced directors. Independent Chairman of the Board Alan Fisher is the most experienced director on the board, commencing their role in 2015. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model. Announcement • Oct 27
IDT Australia Limited, Annual General Meeting, Nov 28, 2022 IDT Australia Limited, Annual General Meeting, Nov 28, 2022, at 10:00 AUS Eastern Standard Time. Location: The offices of K & L Gates Level 25, South Tower Rialto, 525 Collins Street, Melbourne, Melbourne Australia Agenda: To consider Accounts and Reports; To consider Adoption of Remuneration Report; To consider Election of directors; To consider Refresh of the Employee Share Plan; To consider Amendments to the Constitution; To consider Approval of increased 7.1A placement capacity; To consider Appointment of Auditor. Announcement • Oct 10
IDT Australia Limited Announces Board Changes IDT Australia Limited announced that Mr. Mark Simari and Mr. Geoffrey Sam, OAM have been appointed as independent Non-executive Directors of the Company, effective 10 October 2022. The Company also announced that Mr. Hugh Burrill will retire as Director of the Company, effective 10 October 2022, and Mr. Michael Kotsanis has advised the Board of his intention to retire at the conclusion of the 2022 Annual General Meeting. Mark Simari is an experienced and accomplished professional in the health care industry and has over 15 years' Board experience in a diverse range of organisations. Mark is currently Chairman of Careteq Limited, Tali Digital Limited and was the co-Founder of Paragon Care and Managing Director from 2008 to 2018 and recently Non-executive Director from 2019 to 2022. Geoffrey Sam, OAM is currently the Chairperson and independent Non-executive Director of Earlypay Ltd. and independent Non-executive Director of Paragon Care Ltd. He has also held previous independent Non-executive Board positions with listed companies Money 3 Ltd, Hutchinsons Childcare Services Ltd. and was Managing Director of Nova Health Ltd. He is the Co-Founder and Board member of Healthe Care Australia Pty Ltd. Geoffrey holds a Bachelor of Commerce (Accounting and Finance) from UNSW, a Master of Health Administration from UNSW, a Master of Arts (Economics and Social Studies) from the University of Manchester UK and is a Fellow of the Australian Institute of Company Directors. Announcement • Sep 15
IDT Australia Limited Announces Executive Changes IDT Australia Limited announced the following key changes to its executive team. Dr. David Sparling has resigned from the Company as Chief Executive Officer effective 14 September 2022. Mr. Paul McDonald, who has been Head of Quality and Development for IDT since January 2021 will replace Dr. Sparling in the role of Chief Executive Officer on an interim basis, effective immediately. This will provide continuity and aid the transition to a newpermanent CEO. Reported Earnings • Aug 31
Full year 2022 earnings released: AU$0.005 loss per share (vs AU$0.009 profit in FY 2021) Full year 2022 results: AU$0.005 loss per share (down from AU$0.009 profit in FY 2021). Revenue: AU$12.1m (down 28% from FY 2021). Net loss: AU$1.16m (down 155% from profit in FY 2021). Over the last 3 years on average, earnings per share has increased by 101% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings. Announcement • Jul 21
IDT Australia Limited Announces Resignation of Ms. Ancila Desai as Chief Financial Officer IDT Australia Limited provides the following market update. After 2 years in her role as IDT's Chief Financial Officer, Ms. Ancila Desai has announced her intention to leave the Company. Ancila will finish up at IDT later this year to commence her next career opportunity and will assist IDT in the transition to a new CFO. IDT has commenced activities to secure a suitable replacement. Announcement • Jan 29
IDT Australia Limited Appoints Jane Ryan as an Independent Non-Executive Director IDT Australia Limited announced that Dr. Jane Ryan has been appointed as an independent non-executive Director, effective 28 January 2022. Dr. Ryan has over 30 years of international experience in the pharmaceutical and biotechnology industries having worked in Australia, US and UK. She has held senior executive roles in management of research and development programs as well as business development and alliance management. Jane is currently a Non-Executive Director of Anatara Lifesciences Ltd. and Bionomics Ltd. Reported Earnings • Aug 27
Full year 2021 earnings released: EPS AU$0.009 (vs AU$0.008 loss in FY 2020) The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: AU$16.9m (up 20% from FY 2020). Net income: AU$2.10m (up AU$4.02m from FY 2020). Profit margin: 12% (up from net loss in FY 2020). The move to profitability was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 95% per year but the company’s share price has only increased by 71% per year, which means it is significantly lagging earnings growth. Reported Earnings • Feb 24
First half 2021 earnings released: EPS AU$0.005 (vs AU$0.005 loss in 1H 2020) The company reported a decent first half result with improved earnings and profit margins, although revenues were weaker. First half 2021 results: Revenue: AU$5.78m (down 19% from 1H 2020). Net income: AU$1.12m (up AU$2.31m from 1H 2020). Profit margin: 19% (up from net loss in 1H 2020). The move to profitability was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 100% per year but the company’s share price has only increased by 38% per year, which means it is significantly lagging earnings growth. Is New 90 Day High Low • Dec 09
New 90-day high: AU$0.23 The company is up 25% from its price of AU$0.18 on 10 September 2020. The Australian market is up 14% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 17% over the same period. Is New 90 Day High Low • Dec 07
New 90-day high: AU$0.20 The company is up 24% from its price of AU$0.17 on 08 September 2020. The Australian market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 10.0% over the same period. 